Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | Targeting cell cycle checkpoint regulators: ATM and ATR

ATM and ATR have exciting potential as therapeutic targets for the treatment of cancer. In this interview Melinda L. Telli, MD, from Stanford University Medical Center, Stanford, CA, discusses the role of ATM and ATR in the DNA damage response and regulating cell cycle checkpoints, as well as their druggability. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.